Big Data: How VHA Can Be Your Friend

Similar documents
Outline. Contour quality control. Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT)

Automated Plan Quality Check with Scripting. Rajesh Gutti, Ph.D. Clinical Medical Physicist

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia

International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO

Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

Treatment Planning & IGRT Credentialing for NRG SBRT Trials

Radiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali

Leveraging Innovation to Design Future Clinical Trials. Outline. Multi-Institutional Research 7/15/2015

Unleashing Big Data in Oncology: Making Real World Cancer Data Useful

Defining Target Volumes and Organs at Risk: a common language

Quality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety

A Comparison of IMRT and VMAT Technique for the Treatment of Rectal Cancer

REVISITING ICRU VOLUME DEFINITIONS. Eduardo Rosenblatt Vienna, Austria

A TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM *

Clinical Precision for Best Cancer Care. Dee Mathieson Senior Vice President Oncology Business Line Management

The Evolution of RT Techniques for Gynaecological Cancers in a developing country context

Elekta - a partner and world-leading supplier

Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.

SBRT fundamentals. Outline 8/2/2012. Stereotactic Body Radiation Therapy Quality Assurance Educational Session

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH

Illawarra Cancer Care Centre

Vaginal Sparing with Volumetric Modulated Arc Therapy (VMAT) for Rectal Cancer. Scott Boulet BSc, RT(T)

Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation

ART for Cervical Cancer: Dosimetry and Technical Aspects

National Cancer Programme. Work Plan 2014/15

Partial Breast Irradiation using adaptive MRgRT

The Physics of Oesophageal Cancer Radiotherapy

Date Modified: May 29, Clinical Quality Measures for PQRS

IGRT Solution for the Living Patient and the Dynamic Treatment Problem

Silvia Pella, PhD, DABR Brian Doozan, MS South Florida Radiation Oncology Florida Atlantic University Advanced Radiation Physics Boca Raton, Florida

CPT code semantics 8/18/2011. SBRT Planning Case Studies. Spectrum of applications of SBRT. itreat

The TomoTherapy System as a Tool of Differentiation in Quality and Marketability

Elekta MOSAIQ and Philips Pinnacle

From position verification and correction to adaptive RT Adaptive RT and dose accumulation

Protocol of Radiotherapy for Small Cell Lung Cancer

RADIOTHERAPY DEPARTMENT

New Technologies for the Radiotherapy of Prostate Cancer

PROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College

Radiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management

Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery

Maria Golish, CMD, RTT, BS

Image Registration: The Challenge for QA Centers

7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift

Department of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.

How effective is current clinical trial QA

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Feasibility of 4D IMRT Delivery for Hypofractionated High Dose Partial Prostate Treatments

Veterans Health Administration Lung Cancer Screening Demonstration Project: Results & Lessons Learned

Hot topics in Radiation Oncology for the Primary Care Providers

Implementation of Gynaecological IMRT Planning Technique Clinical Guidelines and Constraints. Chloe Pandeli

FEE RULES RADIATION ONCOLOGY FEE SCHEDULE CONTENTS

LA TOMOTERAPIA IN ITALIA: ESPERIENZE A CONFRONTO

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice?

New research in prostate brachytherapy

Date Modified: March 31, Clinical Quality Measures for PQRS

Clinical Education A comprehensive and specific training program. carry out effective treatments from day one

CyberKnife SBRT for Prostate Cancer

Rectal dose and toxicity dosimetric evaluation for various beam arrangements using pencil beam scanning protons with and without rectal spacers

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors

Ashley Pyfferoen, MS, CMD. Gundersen Health Systems La Crosse, WI

MRI Applications in Radiation Oncology:

IMRT RTOG Definitive IMRT for Low Risk Prostate Cancer. All about dose and dose matters, probably Although hormones may matter

The RPC s Evaluation of Advanced Technologies. AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff

Clinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor

Leveraging Your Cancer Registry: A Strategy for Survey Success

Clinical Trial Credentialing:

Report of ICRU Committee on Volume and Dose Specification for Prescribing, Reporting and Recording in Conformal and IMRT A Progress Report

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

HDR Brachytherapy I: Overview of Clinical Application and QA. Disclosures. Learning Objectives 7/23/2014. Consultant, Varian Medical Systems

Original Article. Teyyiba Kanwal, Muhammad Khalid, Syed Ijaz Hussain Shah, Khawar Nadeem

Radiation Therapy: From Fallacy to Science

Cancer Care in the Veterans Health Administration

Stereotactic ablative body radiation for prostate cancer SABR

National Cancer Programme. Work Plan 2015/16

X. Allen Li BGRT. Biologically Based Treatment Planning. Biologically based treatment planning

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April

SBRT TREATMENT PLANNING: TIPS + TRICKS. Rachel A. Hackett CMD, RT(T)

DELIVERED PATIENT DOSE

QA for Clinical Dosimetry with Emphasis on Clinical Trials

Radiation Damage Comparison between Intensity Modulated Radiotherapy (IMRT) and Field-in-field (FIF) Technique In Breast Cancer Treatments

8/2/2017. Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency. Part III

Clinical Implementation of SRS/SBRT

TOMOTERAPIA in Italia: Esperienze a confronto

Evaluation of Monaco treatment planning system for hypofractionated stereotactic volumetric arc radiotherapy of multiple brain metastases

TRANS-TASMAN RADIATION ONCOLOGY GROUP INC. Quality Assurance. Treatment Planning Benchmark

HDR vs. LDR Is One Better Than The Other?

Credentialing for Clinical Trials -IGRT. Evidence Based Radiation Oncology. Levels of Clinical Evidence. Why Credentialing?

MRI Based treatment planning for with focus on prostate cancer. Xinglei Shen, MD Department of Radiation Oncology KUMC

On the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors

Biologically Based Treatment Planning X. Allen Li

Practice teaching course on head and neck cancer management

Comparison of IMRT and VMAT Plan for Advanced Stage Non-Small Cell Lung Cancer Treatment

Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline High-Risk Disease

Reena Phurailatpam. Intensity Modulated Radiation Therapy of Medulloblastoma using Helical TomoTherapy: Initial Experience from planning to delivery

ASTRO econtouring for Lymphoma. Stephanie Terezakis, MD

8/2/2018. Disclosure. Online MR-IG-ART Dosimetry and Dose Accumulation

IMRT - Intensity Modulated Radiotherapy

Transcription:

Big Data: How VHA Can Be Your Friend Jatinder R Palta PhD Rishabh Kapoor MS Michael Hagan PhD, MD National Radiation Oncology Program(10P11H) Veterans Health Administration, USA

Disclosure Vice President, Center for the Assessment of Radiological Sciences (CARS) A non-profit organization dedicated to improving quality and safety of radiotherapy and radiological imaging.

Objectives Discuss value proposition in radiation oncology, Discuss why VHA is a good test laboratory for determining value in radiation oncology, Describe VHAs Radiation Oncology Practice Assessment (ROPA) initiative, Discuss how ROPA can potentially become a model for quality and outcome assessment in radiation oncology.

Value in care defined for the radiation oncologist International Journal of Radiation Oncology Biology Physics 2017,97, 450-459

Stakeholder in the discussion of value in oncology International Journal of Radiation Oncology Biology Physics 2017,97, 450-459

What is big data? Big data is a term for data sets that are so large or complex that traditional data processing application softwares are inadequate to deal with them. (Wiki) Big data is a term that describes the large volume of data both structured and unstructured. Big data can be analyzed for insights that lead to better decisions and strategic business moves. (SAS) Extremely large data sets that may be analyzed computationally to reveal patterns, trends, and associations. (Dictionary) 5 V ; Volume, Velocity, Variety, Veracity, and Value

The Surveillance, Epidemiology, & End Results (SEER) Registries Includes approximately 28% of US Population Representative sample of all ethnicities and socio-economic backgrounds Limitations Limited information about key health factors Inaccuracy; such as under ascertainment of outpatient treatments, Migration/loss to follow-up Sparse to no RT data States included in SEER Registries; SEER 9, 13 &18

Big Data in Cancer Care From Presentation by Todd McNutt, JHU @Target-Insight, Toronto Ca, 2015

Big data Challenges in Radiation Oncology siloed data elements International Journal of Radiation Oncology Biology Physics 2017,97, 450-459

Veteran Health Administration Largest Integrated Health care system in United States. 1,233 health care facilities Incl. 168 VA Medical Centers 1,053 outpatient clinics Serving more than 8.9 million Veteran each year. Annual budget: $69 billion (2017) Single interconnected electronic medical record system (VISTA CPRS) since 1983

VHA Radiation Oncology Centers 40 Centers in 18 regions across the U.S.

Radiation Oncology in VHA 40 Radiation Oncology VA clinics 15,000 patients treated in-house 25,000 patient sent outside for RT. 70+ treating radiation oncologists 70+ therapeutic medical physicists 72 linear accelerators Longitudinal history of patients RT episode in Vista/CPRS.

Time Points for Data Collection CPRS From Presentation by Todd McNutt, JHU @Target-Insight, Toronto Ca, 2015

VHA Radiation Oncology Practice Assessment(ROPA) Purpose: Assessment of radiation delivery and cancer related outcomes for the VHA radiation oncology practices Background: Disease-site expert panels of the American Society for Radiation Oncology (ASTRO) have identified clinical measures and associated data fields to assess the quality of radiation treatments These clinical measures will be used by the VHA to monitor the quality of radiation oncology and outcome assessment Pilot: Prostate and Lung Cancer

Scope of Data Acquisition Manual abstraction by visit to 40 VA Radiation Oncology Centers. Comprehensive evaluation of 50 cases from each center, 20-30 ASTRO vetted metrics per case 20 cases - prostate cancer: T1c T3, NX0M0 (Intermediate or high risk per NCCN criteria) 20 cases Non-Small Cell Lung Cancer (NSCLC): Stages IIIA and IIIB 10 cases Small Cell Lung Cancer (SCLC): Limited Stage. Most recent, serial cases in each category who have completed post-treatment follow-up examination

Data Collection for ROPA Data Sources Clinical data Abstracted from physicians clinical note templates in CPRS used by clinicians in their routine process of care Radiation treatment management data Abstracted from RT-EMR (e.g. ARIA, MOSAIQ) Treatment Planning Data DICOM/DICOM-RT data abstracted from treatment planning systems (e.g. Eclipse, Pinnacle, XiO, Hi-ART ) Data Abstraction Requirements No Protected Health Information (PHI) will be recorded. Treatment dates to be recorded as elapsed time from offset.

Quality Measures Clinical Measures Defined by ASTRO Disease Site Expert Panels Measures with published data that will be utilized for the practice assessment. Aspirational Measures VA asked the panels to also provide ambitious goals or items not currently in common practice that reflect high quality. Examples: Quality of life assessment prior to treatment completion, Survivorship Care Plans. Surveillance Measures Measures that either do not yet have enough published data to demonstrate a link to quality (i.e. collection of molecular information) or are focused on population health (enrollment on clinical trials).

MEASURE #3: Imaging/Staging for High Risk Numerator Statement Denominator Statement Patients with imaging for staging, prior to the initiation of treatment, that includes: 1. CT or MRI, AND 2. Bone scan (T 99 or NaF PET). All patients, regardless of age, with a diagnosis of prostate cancer, at high OR very high risk as defined by NCCN guidelines, receiving radiation therapy Denominator Exclusions/Exceptions Patients treated post prostatectomy Notes Consensus Survey Results: 100% Expected Performance Rate Timeframe Higher = better Panel Vote: 95% CMS PQRS Measure #102 (Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients). Average Performance Rate in 2011: 95.4%. in 2012: 92.9%; in 2013: 90.6% Prior to first treatment

DVH Metric Types Constraint Metric will be used to evaluate the plan and provider s performance Informational For the purposes of data collection Not to be used to judge the appropriateness of a plan DVH Metric Scale Most DVH Constraints and DVH Informational Metrics were divided into a 3 tiered system Green: Pass Warning Red: Fail

Lung Quality Measures

Spinal Cord Dmax* Metrics Varying Fractionation Limit Green Yellow Red Mandatory Constraint vs. Informational Source Fractionation 50 Gy <= 45 Gy >45 Gy <= 50 Gy > 50 Gy Constraint QUANTEC Standard 41 Gy <=36.9 Gy >36.9 Gy <= 41 Gy > 41 Gy Constraint Turrisi, NEJM 1998, RTOG 0538 Hyper 37 Gy <=33.3 Gy >33.3 Gy <= 37 Gy > 37 Gy Constraint BED calc (ab = 3, EQD2 = 49.6 Gy) Hypo - 10 42 Gy <= 37.8 Gy >37.8 Gy <= 42 Gy > 42 Gy Constraint Timmerman / USC, confirmed w/bed (ab = 3, EQD2 = 48.7 Gy) Hypo - 15 *Dose to <0.035 cc

Various Lung Metrics Standard Fractionation Metric Limit Green Yellow Red Mandatory Constraint vs. Informational Source Note* V20 Gy 37% <= 33% > 33% <= 37% > 37% Constraint QUANTEC 2 lungs V5 Gy 60% <= 54% > 54% <= 60% > 60% Informational RTOG 1308 2 lungs Dmean 20 Gy <= 18 Gy > 18 Gy <= 20 Gy > 20 Gy Informational QUANTEC 2 lungs V20 Gy 7% <= 6.3% > 6.3% <= 7% > 7% Constraint V5 Gy 60% <= 54% > 54% <= 60% > 60% Informational Dmean 8.5 Gy <= 7.7 Gy > 7.7 Gy <= 8.5 Gy > 8.5 Gy Constraint Rice et al, IJROBP 2007 Allen et al, IJROBP 2007 Rice et al, IJROBP 2007 1 lung 1 lung 1 lung *Total Lung - XXX. In order of availability, GTV>ITV>CTV>PTV

Esophagus Metrics Standard Fractionation Metric Limit Green Yellow Red Mandatory Constraint vs. Informational Source V60 Gy 17% <= 15.3 % > 15.3% <= 17 % > 17% Informational Palma et al, IJROBP 2014 Dmean 34 Gy <= 30.6 Gy > 30.6 Gy <= 34 Gy > 34 Gy Informational QUANTEC Dmax* 74 Gy <= 66.6 Gy > 66.6 Gy <= 74 Gy > 74 Gy Informational RTOG 1308 * Dose to <0.035 cc

Other Metrics Standard Fractionation OAR Metric Limit Green Yellow Red Mandatory Constraint vs. Informational Source Brachial Plexus Dmax* 66 Gy <= 59.4 Gy > 59.4 Gy <= 66 Gy > 66 Gy Constraint QUANTEC Heart V45Gy 35% <= 31.5% > 31.5% <= 35% > 35 % Informational RTOG 1308 PTV D95% 100% Rx 100% >= 95% < 100% < 95% Constraint RTOG 1308 PTV Dmin* 85% Rx >85% >= 75% < 85% < 75% Informational RTOG 1308 * Dose to <0.035 cc

Prostate Quality Measures

Rectum Metrics External Beam, Varying Fractionation Metric Limit Green Yellow Red Mandatory Constraint vs. Informational Source Fractionation V70 Gy* 25% <=25% >25% Constraint RTOG 0126, 0415, 0815 Standard V69 Gy 25% <=25% >25% Informational RTOG 0415 Hypo V70 Gy 15% <=15% >15% Informational V75 Gy 10% <=10% >10% Informational Michalski et al, IJROBP 2013 Michalski et al, IJROBP 2013 Standard Standard V50 Gy 50% <=50% >50% Constraint QUANTEC Standard *Should be met in >= 90% of cases

Bladder, Femurs Metrics External Beam, Standard Fractionation OAR Metric Limit Green Yellow Red Mandatory Constraint vs. Informational Source Bladder* V70 Gy 35% <=35% >35% Informational Bladder V65 Gy 50% <=50% >50% Informational QUANTEC, RTOG 0126, 0415, 0815 QUANTEC, RTOG 0126, 0415, 0816 Femurs V50 Gy 10% <=10% >10% Informational RTOG 0534 *Should be met in >= 90% of cases

Bowel Metrics External Beam, Standard Fractionation OAR Metric Limit Green Yellow Red Mandatory Constraint vs. Informational Source Bladder V70 Gy 35% <=35% >35% Informational Bladder V65 Gy 50% <=50% >50% Informational QUANTEC, RTOG 0126, 0415, 0815 QUANTEC, RTOG 0126, 0415, 0816 Femurs V50 Gy 10% <=10% >10% Informational RTOG 0534 *Volume is Bladder minus CTV

VHA ROPA Workflow

VHA ROPA Deliverables Facility reports: detailed radiation delivery parameters and outcomes, nationally benchmarked for 50 cases VHA global report: examines variability within VHA Benefit to the VHA enterprise: Roadmap for continuous improvement for each in-house radiation oncology practice Identification of metrics for future internal, remote evaluations using VA s EMR (CPRS) Parallel Effort Electronic abstraction of data fields for clinical measures directly from different data sources and performing periodic remote electronic re-assessment.

VHA ROPA Data Sources Clinical data Abstracted from disease-site specific clinical note templates in CPRS used by clinicians in their routine process of care Radiation treatment management Abstracted from RT-EMR (e.g. ARIA, MOSAIQ) Treatment Planning Data DICOM/DICOM-RT data abstracted from treatment planning systems Patient Reported Outcome data from Patient Portals Electronic Data Abstraction Deployment of the data aggregation software at the local facility Aggregation of data at various time points in the treatment process Data integrity, completeness and validation check Deployment of the Enterprise Central QA Database Aggregate data from all VA facilities. Tools for data analysis, national benchmarking and analysis of variability within VHA

Disease Site Specific Smart Templates in Radiation Oncology Consensus clinical templates for all major disease sites treated with RT, Initial consultation, treatment planning, treatment, end of treatment, and follow up notes, Designed to prepopulate data from CPRS s patient chart and subsequent notes seamlessly.

Disease Site Specific Smart Templates in CPRS Clinical Templates with Discrete Codified Data Elements

Data abstracted from Consult template used to prepopulated Treatment planning template

Work Flow Templates in CPRS

Summary Quality care is one of the dominant issues in health care today, especially in radiation oncology, Quality care data are most complex in radiation oncology but structured, Quality of care is best assessed from the perspective of structure, process, and outcome measures. VHA is leading the nation in establishing an electronic infrastructure that will automatically abstract data from clinical workflow templates to assess the quality of radiotherapy and outcomes.